Giving your patients up to 180 days of freedom
Introduction to Eversense
Eversense XL is the world’s first long-term CGM, with excellent1 accuracy and a fully insertable sensor that lasts for up to 180 days.
It can help patients better manage their diabetes1 by providing real-time insight into their changing glucose levels, which can be discreetly checked on compatible mobile devices.
Roche Diabetes Care are proud to collaborate with Senseonics Incorporated to distribute the Eversense XL in the UK.
Unlike ordinary glucose sensors, the Eversense XL Sensor is professionally implanted in the upper arm beneath the skin's surface.
Encased in a biocompatible material, the sensor uses fluorescence-based technology to measure glucose in the interstitial fluid that reversibly binds to the glucose-indicating polymer. The measurement and display of glucose values are both done automatically, without the need for user intervention.
- Sensor lasts up to 180 days — no weekly sensor insertions
- Professional insertion and removal in doctor’s surgery
- Fully implanted sensor
- Accurate throughout the sensor life with a MARD of 11.6%2
Removable, rechargeable, and water-resistant3
The Eversense XL Smart Transmitter is worn over your sensor and wirelessly powers it to activate the transfer of glucose measurements. The smart transmitter receives glucose data from the sensor, and sends glucose values via Bluetooth to the Eversense Mobile App.
On body vibe alerts are provided by your smart transmitter even when the mobile device is not nearby. With its super-slim design, sleek rounded shape, and water resistance, the Eversense XL Smart Transmitter easily fits into your patients life.
The Eversense Mobile App runs on a compatible mobile device to receive and display the sensor glucose data from the Eversense Smart Transmitter.
It provides easy access to real-time glucose measurements and eliminates the need to carry a separate receiver device.
In addition to seeing current glucose values every 5 minutes, the app also displays where the glucose is headed and how fast, and provides alerts and notifications via the mobile device, so actions can be taken confidently.
Features to help patients manage their diabetes
- Set unique sounds for glucose alerts
- Set up a temporary glucose profile with custom high and low targets and alert levels
- Receive predictive alerts to highlight in advance if glucose is moving toward a high or low event
- Track events like meals and workouts and see them on a graph to help identify trends
- View summary reports to better understand glucose history and patterns
Not just better health, a better quality of life
Having diabetes is hard enough. Eversense wants to help make it easier for your patients to manage. As part of a European clinical trial, Eversense users were asked how Eversense impacted their life.4
- 85% had increased confidence over their diabetes control
- 90% said it made living with diabetes less of a burden
- 76% felt more confident about avoiding severe hyproglycemia
- 88% said it helped them deal more easily with their diabetes
- 72% felt safer when sleeping
NICE criteria for recommending CGM
The National Institute for Health and Care Excellence (NICE) recommend in its 2015 clinical guidelines, covering the management of Type 1 diabetes in adults (NG17)5 and children (NG18)6, that continuous glucose monitoring (CGM) is offered to people that meet specific situations.
- If having more than one severe hypoglycaemic event a year that is brought on by no obviously preventable cause
- A complete loss of hypo awareness
- Frequent episodes of problematic hypos occuring without symptoms
- If an extreme fear of hypoglycaemia is causing problems or distress
- If unable to achieve an HbA1c of under 75 mmol/mol (9%) despite testing blood sugar levels at least 10 times a day
CGM use can be applied if the following factors also apply:
- The intended user of the CGM is willing both to commit to using the CGM at least 70% of the time and keep it regularly calibrated
- The user is on multiple daily injections or insulin pump therapy
- The health team providing the CGM has the expertise to advise on effective use of the CGM
The multicentre European PRECISE Study (Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor) aimed to determine the accuracy and safety of the Eversense Continuous Glucose Monitoring (CGM) system over successive periods of 30 days for up to 6 months.1
With regard to accuracy, the primary endpoint of MARD (mean absolute relative difference) was 11.6% over the range of 2.2 - 22 mmol/L against venous glucose references (using YSI2300 Stat Plus).
Average reduction in HbA1c over 180 days was 0.35%.
Wear-time compliance for the smart transmitter was good, with a median wear time of 23.5 hours/day (mean 22.3 hours/day). There were no significant adverse events.
Overall participants scored the Eversense CGM system very high on ease of use, convenience, and comfort. Participants were able to wear the transmitter in their everyday setting throughout 180 days of wear. Most stated they would have the Eversense CGM system inserted again.7
- Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S. C., Kapitza, C., ... & DeVries, J. H. (2017). Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial. Diabetes Care, 40(1), 63-68.
- 2.2-22.2 mmol/L (40-400 mg/dL). Aronson R, Abitbol A, Tweden KS. First assessment of the performance of an implantable continuous glucose monitoring system
through 180 days in a primarily adolescent population with type 1 diabetes. Diabetes Obes Metab. 2019;21(7):1689-94.
- Water resistant Smart Transmitter submerged up to 1 meter for up to 30 minutes.
- Beck RW, MD, Hirsch IB, La_el L, Tamborlane WV, et al. E_ect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care. 2009 August; 32(8): 1378–1383.
- National Institute for Health and Care Excellence (NICE). (NG17). Type 1 diabetes in adults: diagnosis and management. August 2015.
- NICE (NG18). Diabetes (type 1 and type 2) in children and young people: diagnosis and management. August 2015.
- Barnard K et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology. Published October 8, 2017. (https://doi.org/10.1177%2F1932296817735123)